Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

7 Apr 2011
Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

7 Apr 2011
ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

6 Apr 2011
Celldex presents CDX-1127 preclinical data against cancer at AACR meeting

Celldex presents CDX-1127 preclinical data against cancer at AACR meeting

6 Apr 2011
NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

6 Apr 2011
Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

1 Apr 2011
New research finds HIV virus's V3 loop as attractive vaccine target

New research finds HIV virus's V3 loop as attractive vaccine target

1 Apr 2011
Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

1 Apr 2011
Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

31 Mar 2011
Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck submits Erbitux indication extension to EMA for NSCLC treatment

30 Mar 2011
AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

28 Mar 2011
U.S. FDA approves Yervoy to treat patients with late-stage melanoma

U.S. FDA approves Yervoy to treat patients with late-stage melanoma

28 Mar 2011
FDA approves ipilimumab for metastatic melanoma treatment

FDA approves ipilimumab for metastatic melanoma treatment

28 Mar 2011
BMY receives FDA approval for YERVOY to treat metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

28 Mar 2011
Almac extends Pharma Services business unit to increase demand for storage capacity

Almac extends Pharma Services business unit to increase demand for storage capacity

25 Mar 2011
KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios commences KB004 Phase 1 trial in patients with leukemia

24 Mar 2011
Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

23 Mar 2011
SGEN, Abbott enter collaboration agreement for ADC products

SGEN, Abbott enter collaboration agreement for ADC products

23 Mar 2011
NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

21 Mar 2011
EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

18 Mar 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback